Bibliography
- van den Beuken-van Everdingen MH , de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann. Oncol.18 , 1437–1449 (2007).
- Breivik H , ChernyN, CollettB et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann. Oncol. 20 , 1420–1433 (2009).
- Zech DF , GrondS, LynchJ, HertelD, LehmannKA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain63 , 65–76 (1995).
- Blasco A , BerzosaM, IranzoV, CampsC. Update in cancer pain. Cancer Chemother. Rev.4 , 95–109 (2009).
- Böhme K , LikarR. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study. Pain Clinic15 , 193–202 (2003).
- Sittl R , GriessingerN, LikarR. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin. Ther.25 , 150–168 (2003).
- Sorge J , SittlR. Transdermal buprenorphine in the treatment of chronic pain: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther.26 , 1808–1820 (2004).
- Poulain P , DenierW, DoumaJ et al. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J. Pain Symptom Manage. 36 , 117–125 (2008).
- Schmitz S , BruchHR, Hagen-AukampC. Transdermal buprenorphine in patients with cancer-related pain in oncological practice. J. Appl. Ther. Res.6 , 20–31 (2008).
- Muriel C , FaildeI, MicóJA, NeiraM, Sánchez-MagroI. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin. Ther.27 , 451–462 (2005).
- Camba MA , Rodríguez-LópezMJ, Muriel C; Grupo de Studio de Opioides de la Socieda Española del Dolor. Buprenorphine TDS in the treatment of chronic nociceptive, neuropathic and cancer-related pain. J. Appl. Ther. Res.6 , 3–13 (2007).
- Griessinger N , SittlR, LikarR. Transdermal buprenorphine in clinical practice – a post-marketing surveillance study in 13179 patients. Curr. Med. Res. Opin.21 , 1147–1156 (2005).
- Sacerdote P . Opioid-induced immunosuppression. Curr. Opin. Support. Palliat. Care2 , 14–18 (2008).
- Pergolizzi J , AloisiAM, DahanA et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 10 , 428–450 (2010).
- Ferreira KA , KimuraM, TeixeiraMJ et al.Impact of cancer-related symptom synergisms on health-related quality of life and performance status. J. Pain Symptom Manage.35 , 604–616 (2008).
- Strang P . Emotional and social aspects of cancer pain. Acta Oncol.31 , 323–326 (1992).
- Bottomley A , Aaronson NK; European Organisation for Research and Treatment of Cancer. International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. J. Clin. Oncol.25 , 5082–5086 (2007).
- Montazeri A . Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual. Life Outcomes7 , 102 (2009).
- Davidson JR , MacLeanAW, BrundageMD, SchulzeK. Sleep disturbance in cancer patients. Soc. Sci. Med.54 , 1309–1321 (2002).
- Brennan MJ , LiebermanJA 3rd. Sleep disturbances in patients with chronic pain: effectively managing opioid analgesia to improve outcomes. Curr. Med. Res. Opin.25 , 1045–1055 (2009).
▪ Websites
- WHO. WHO‘s Pain Ladder www.who.int/cancer/palliative/painladder/en (Accessed 8November2010)
- The British Pain Society. Cancer pain management www.britishpainsociety.org (Accessed 10November2010)